Profiel
Gavin B.
Samuels is Senior Vice President of Business Development for Quark Pharmaceuticals, Inc. Prior to joining Quark Pharmaceuticals March, 2007 he held several positions at Worldwide Business Development and Worldwide Product Development Groups for Pfizer, Inc. Previously, he was Senior Associate of Healthcare Strategy and Corporate Affairs for Merck Sharpe & Dohme in Australia.
Dr. Samuels received an MS from the University of Witwatersrand, an MBA from the University of New England (Australia) and a degree in Health Economics from Monash University, Australia.
Eerdere bekende functies van Gavin B. Samuels
Bedrijven | Functie | Einde |
---|---|---|
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Corporate Officer/Principal | 23-09-2010 |
PFIZER, INC. | Corporate Officer/Principal | - |
Opleiding van Gavin B. Samuels
University of the Witwatersrand | Doctorate Degree |
University of New England (Australia) | Masters Business Admin |
Monash University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
PFIZER, INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |